1Wasley A, Alter M. Epidemiology of hepatitis C: geographic differences and temporal trends[J]. Semin Liver Dis, 2000, 20: 1-16.
2Drusano GL, Preston SL. A 48 week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus[J]. J Infect Dis, 2004, 89(6): 964-970.
3Nakamura H, Uyama H, Enomoto H, et al. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C[J]. Hepatogastroenterology, 2003, 50(49): 222-226.
4Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy[J]. J Viral Hep, 1999, 10: 165-181.
5Rumin S, Berthillon P, Tanaka E, et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro[J]. J Gen Virol, 1999, 80(Pt 11): 3007-3018.
6Iacovacci S, Manzin A, Barca S, et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro[J]. Hepatology, 1997, 26(5): 1328-1337.
7Yoshikura H, Hijikata M, Nakajima N, et al. Replication of hepatitis C virus[J]. J Viral Hepat, 1996, 3(1): 3-10.
8Nakajima N, Hijikata M, Yoshikura H, et al. Characterization of long-term cultures of hepatitis C virus[J]. J Virol, 1996, 70(5): 3325-3329.
9Poynard T, Ratziu V, Benhamou Y, et al. Natural history of HCV infection[J]. Baillieres Best Pract Res Clin Gastroenterol, 2000, 14: 211-228.
10Shimizu YK, Iwamoto A, Hijikata M, et al. Evidence for in vitro replication of hepatitis c virus genome in a human T-cell line[J]. Proc Natl Acad Sci USA, 1992, 89(12): 5477-5481.
